A story from the Financial Times identifies a new trend: funds investing in cause-based companies to get new treatments and diagnostics in development for the benefit of overlooked patients. But if market reforms don’t follow, the number of new tools and treatments won’t find the conventional financial investors they need to help millions of people.
“If we don’t get some policy changes and develop the right financial incentives to reward risk taking in innovation, then the little innovation we have will, I think, dry up nearly completely,” says Henry Skinner, CEO of the AMR Action Fund. “We will not have the antibiotics we need in future decades.” Read the full article here.
